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Monozygotic (MZ) twins are partially concordant for most complex diseases, including autoimmune disorders. Whereas
phenotypic concordance can be used to study heritability, discordance suggests the role of non-genetic factors. In au-
toimmune diseases, environmentally driven epigenetic changes are thought to contribute to their etiology. Here we
report the first high-throughput and candidate sequence analyses of DNA methylation to investigate discordance for
autoimmune disease in twins. We used a cohort of MZ twins discordant for three diseases whose clinical signs often
overlap: systemic lupus erythematosus (SLE), rheumatoid arthritis, and dermatomyositis. Only MZ twins discordant for
SLE featured widespread changes in the DNA methylation status of a significant number of genes. Gene ontology analysis
revealed enrichment in categories associated with immune function. Individual analysis confirmed the existence of DNA
methylation and expression changes in genes relevant to SLE pathogenesis. These changes occurred in parallel with
a global decrease in the 5-methylcytosine content that was concomitantly accompanied with changes in DNA methylation
and expression levels of ribosomal RNA genes, although no changes in repetitive sequences were found. Our findings not
only identify potentially relevant DNA methylation markers for the clinical characterization of SLE patients but also
support the notion that epigenetic changes may be critical in the clinical manifestations of autoimmune disease.
[Supplemental material is available online at http://www.genome.org. The sequence data from this study have been
submitted to the NCBI Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo) under accession no. GSE19033.]
Human monozygotic (MZ) twins exhibit variable degrees of concor-
dance for complex diseases, such as cancer, cardiovascular diseases, or
autoimmune disorders. Whereas concordance rates close to 100% in
identical twins apply to coinheritance of mutant genes that are
dominant and highly penetrant, most diseases or traits show a con-
cordance in identical twins in the broad range of 5%–75% (Nance
1978). Most of the twin-based studies have focused on the concor-
dance between siblings that has led to the identification of trait-
specific genes (Hrubec and Robinette 1984), while less attention has
been paid to the degree of discordance, which suggests the partici-
pation of factors other than pure genetic changes. Recently, interest
has shifted toward exploring the molecular mechanisms involved in
determining phenotypic differences. The increasing recognition of
the influence of epigenetics in phenotypic outcomes continues to
open up new lines of research involving twin studies. DNA methyl-
ation and histone modifications, the major sources of epigenetic in-
formation, regulate gene expression levels and provide an alternative
mechanism for modulating gene function to those arising from ge-
netic changes (Esteller 2008). Interestingly, epigenetic changes are
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highly dependent on environmental factors, and recent data support
the notion that diet and other external influences can alter the epi-
genetic status of genes (Mann et al. 2004; Heijmans et al. 2008).
In the case of autoimmune disorders, twin studies have pro-
vided evidence of the existence of a genetic component and have
been useful for identifying susceptibility genes. One of the best
studied autoimmune diseases is systemic lupus erythematosus
(SLE), an archetypical systemic, autoimmune inflammatory dis-
ease characterized by the production of autoantibodies to multiple
nuclear antigens. Well-established risk factors include alleles in
the major histocompatibility complex region, IRF5, STAT4, BLK,
BANK1, PDCD1, MECP2, and TNFSF4, among others (Graham
et al. 2007; International Consortium for Systemic Lupus Erythe-
matosus Genetics 2008; Moser et al. 2009). Many SLE suscepti-
bility genes belong to key pathways that are common to those
associated with other autoimmune disorders. In fact, not only
genetic factors but also clinical signs and symptoms of SLE overlap
with those of other autoimmune diseases such as rheumatoid ar-
thritis (RA) or dermatomyositis (DM) (Encinas and Kuchroo 2000)
(a summary of clinical features of these three diseases is presented
in Supplemental Table 1).
In addition to twin discordance, additional evidence high-
lights the relevance of epigenetic events in the etiology of SLE and
other autoimmune diseases. Lymphocytes from patients with SLE
and RA exhibit globally hypomethylated DNA (Richardson et al.
1990; Corvetta et al. 1991). In parallel, DNA methylation analysis of
several candidate genes in lymphocytes from SLE individuals has
identified promoter demethylation that may contribute to their
aberrant overexpression. These changes occur in PRF1 (Kaplan et al.
2004), CD70 (Lu et al. 2005), ITGAL (Lu et al. 2002), and the X
chromosome gene CD40LG (Lu et al. 2007) promoters, and are
known to be associated with the development of lupus. Additional
evidence of the role of DNA methylation changes in the de-
velopment of SLE comes from studies of DNA demethylating drugs.
For instance, CD4+ T-cells become autoreactive following treatment
with 5-azacytidine (Richardson 1986), which causes genome-wide
hypomethylation and aberrant overexpression of many genes.
Direct comparison of identical twins is an excellent experi-
mental approach for testing environmental epigenetics, because
DNA sequence differences, including single-nucleotide poly-
morphisms, which would be abundant in singleton-based studies,
do not interfere in this analysis. Recent studies with twins (Fraga
et al. 2005; Kaminsky et al. 2009) have demonstrated the exis-
tence of genome-wide epigenetic differences that potentially
could explain differences in phenotype. Here, we used a col-
lection of identical twins discordant for SLE and two other re-
lated systemic autoimmune diseases to perform the first high-
throughput analysis of DNA methylation changes. Interestingly,
only SLE samples exhibited significant changes in DNA methyl-
ation status at both the global and sequence-specific levels in
comparison with their healthy, discordant twins and compared
with unrelated matched normal controls. Our study allowed us to
identify differential methylation between SLE and healthy twins
in a set of genes with biological functions relevant to SLE patho-
genesis. We also found a global decrease in global 5-methyl-
cytosine (5mC) content when comparing SLE twins with their
corresponding healthy twins. We also observed a change in DNA
methylation status of the CpG-rich region of the ribosomal DNA
repeat, which contains the transcribed 18S and 28S genes. Our
twin study provides the first evidence that large changes in the
DNA methylation profile may be associated with the differential
onset of the disease in twins discordant for SLE, suggesting that
there is an association with environmental effects. In addition,
our study also yields a list of epigenetically deregulated DNA se-
quences in SLE, which may potentially lead to a better un-
derstanding of its pathogenesis.
Results
DNA methylation profiling reveals differences in MZ twins
discordant for SLE
To investigate the existence of gene-specific DNA methylation
changes associated with the development of the disease in MZ
twins discordant for SLE, RA, and DM, we used a high-throughput
approach. Samples had been collected when the affected twins
showed signs of disease activity. Specifically, we performed DNA
methylation profiling using universal bead arrays (Bibikova et al.
2006) with 60 samples corresponding to DNA extracted from white
blood cells (WBCs) of 30 MZ twins discordant for SLE, RA, and DM
(five twin pairs of each disease), and 30 unrelated normal controls
matching by pairs in age, gender, and race with the MZ twin pairs
studied. This bead array interrogates the DNA methylation status
of 807 CpG-containing promoters of genes classified in various
groups such as those pertaining to cell cycle control, differentia-
tion, apoptosis, imprinting, and so on. This approach enabled us to
obtain highly reproducible DNA methylation profiles. Scatterplots
comparing the average DNA methylation patterns of the five MZ
twins discordant for each RA and DM illustrate the absence of
differences (Fig. 1A), indicating that, at least for the 807 promoters
represented in this array, there had been no significant changes in
DNA methylation status in these two diseases. In contrast, when
comparing the five SLE pairs of discordant MZ twins, we found
a common set of genes exhibiting differential DNA methylation in
SLE twins compared with their healthy twins. Statistical analysis of
the combined data from the five MZ twins discordant for SLE
showed that 49 genes had significant differences in DNA methyl-
ation (b > 0.10, P-value < 0.05, Student’s t-test) between SLE and
healthy MZ twins (Fig. 1B,D; Supplemental Table 2). The com-
parisons between MZ twins, which are genetically identical, avoid
the effects of any potential interference that SNPs might cause in
this sort of analysis. The specificity of the differences observed is
highlighted by the fact that those changes corresponding to the
average of five pairs of MZ twins discordant for SLE were almost
identical to the pattern obtained for each of the individual MZ
twin pairs (Fig. 1, cf. left panels of B and C). Correlation between
cell subfractions (as obtained by automated complete blood
counts) and methylation data of these 49 genes confirmed that the
methylation differences observed in WBC samples were not due to
cell subfraction changes. The fact that the level of difference is
moderate is not unexpected, given the heterogeneous nature of
human subjects and lupus syndromes as well as the complex na-
ture of the biological samples used in this study. It is of particular
interest that this set of 49 genes, which are differentially methyl-
ated in SLE and healthy MZ twins, showed no significant meth-
ylation changes when compared with the DNA methylation pro-
files of the five pairs of unrelated normal controls matched by age,
gender, and race (see right panels of Fig. 1B,C), suggesting that the
aforementioned DNA methylation differences are specific to the
different phenotypes of SLE and healthy twins.
We then set out to determine whether the 49 differentially
methylated genes could be involved in biological functions rele-
vant to the pathogenesis of SLE. As a first step, we performed Gene
Ontology analysis to test whether some molecular functions,
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biological processes, or the cellular components were significantly
associated with the genes with the greatest difference in DNA
methylation status between the SLE discordant MZ twins. In-
terestingly, we observed significantly enriched functional pro-
cesses that are potentially relevant in autoimmune inflammatory
diseases, including the following categories: defense response
(GO:0006952), cell activation (GO:0001775), immune response
(GO:0006955), cell proliferation (GO:0008283), or cytokine pro-
duction (GO:0001816) (see Supplemental Table 3). This range of
associated functions suggests potential cell types and biological
pathways affected by these aberrant DNA methylation changes.
To confirm that these differences in DNA methylation be-
tween SLE discordant MZ twins were robust, we carried out bi-
sulfite genomic sequencing of multiple clones within promoter
regions of selected genes comprising the fragment corresponding
to the oligonucleotide probe represented in the methylation array.
This experiment allowed us not only to confirm the existence of
DNA methylation changes in these genes, but also to analyze the
regions neighboring the CpG sites included in the bead array. We
chose the following genes, given the level of difference in meth-
ylation revealed by the methylation arrays, their functional rele-
vance, or existing literature: IFNGR2, MMP14, LCN2, CSF3R,
PECAM1, CD9, AIM2, and PDX1. To confirm the previous analysis,
we chose two MZ twin pairs discordant for SLE, two MZ twin pairs
concordant for SLE, two healthy MZ twin pairs, and two unrelated
healthy race-, gender-, and age-matched controls (several exam-
ples are shown in Supplemental Fig. 1). This analysis confirmed the
existence of DNA methylation differences between SLE-discordant
MZ twins. In addition, it showed that the levels of methylation for
these genes in the SLE sibling are comparable to those observed in
each of the individuals of concordant SLE twin pairs. To gather
further evidence from a wider selection of samples, we pyrose-
quenced a set of 17 pairs of siblings discordant for SLE. In addition
to the first set of five pairs of MZ twins, we included one additional
pair of MZ twins, four dizygotic (DZ) twin pairs discordant for SLE,
and seven pairs of non-twin siblings within 4 yr of age discordant for
Figure 1. Representative scatterplots showing methylation profiles of twins with the three autoimmune diseases studied (SLE, RA, and DM) compared
with their respective healthy twins. (A) Scatterplots corresponding to the average data from five MZ twin pairs discordant for RA (left) and DM (right). (Red)
Genes with significant differences in averaged results from five SLE-discordant MZ twin pairs (see below). (B) (Left) Scatterplot corresponding to the
averaged results from five SLE-discordant MZ twin pairs. (Right) Comparison of the averaged data of five pairs of unrelated controls matched by race, age,
and gender with samples from the left panel. (Red) Significant genes (b > 0.10, P < 0.05). (C ) (Left) A comparison of a single SLE-discordant MZ twin pair.
(Red) Genes with significant differences in averaged results from five MZ twin pairs (see above). (D) Heat map including the data for the 49 genes (54
probes) showing differential methylation between SLE affected and healthy MZ twin pairs (five samples were included). Five additional age-, gender-, and
race-healthy controls for each of the five MZ twin pairs are also included. Data from the Illumina array have been normalized as follows: xi = (xi 
row.mean[i ])/(0.333 3 row.sd[i ]). A scale is shown at the bottom, whereby positive (red) and negative (blue) values correspond, respectively, to a higher
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SLE. We observed a remarkable decrease in the DNA methylation
levels of SLE subjects with respect to their corresponding healthy
siblings for the majority of genes tested (Fig. 2), regardless of whether
the subject pairs were MZ twins, DZ twins, or non-twin siblings
discordant for SLE. A Student’s t-test revealed that seven of the eight
genes (IFNGR2, MMP14, LCN2, CSF3R, PECAM1, CD9, and AIM2,
but not PDX1) exhibited a significant reduction (P < 0.05) in their
DNA methylation levels between SLE and corresponding healthy
siblings, indicating that these changes in the DNA methylation
profile are robust. We examined by Pearson test the relationship
between DNA methylation changes in these genes and clinical data
from the SLE individuals (activity and damage indexes), age and
race. No significant correlation was observed, although a larger
population size might be necessary for such analysis.
DNA methylation changes within the promoter region of
a gene are likely to modulate their expression levels. To investigate
this possibility, we performed quantita-
tive RT-PCR to compare the expression
levels of these seven genes for the five
MZ twin pairs discordant for SLE. We
found that for most of the genes tested
(IFGNR2, MMP14, LCN2, CSF3R, and
AIM2), the observed reduction in their
DNA methylation status was correlated
with increased expression levels when
comparing SLE individuals versus their
corresponding healthy siblings (Supple-
mental Fig. 2A).
Global loss of 5-methylcytosine in SLE
twins is not associated with changes at
Alu, Satellite2, D4Z4, and NBL2 repeats
Previous findings from other laborato-
ries have shown decreased global DNA
methylation levels to be associated
with the development of SLE and RA
(Richardson et al. 1990; Corvetta et al.
1991). In order to establish the existence
of global DNA methylation changes in
our set of samples, we measured the total
content of 5mC in the same 17 pairs of
siblings discordant for SLE. We observed
a robust decrease in the 5mC content of
SLE individuals compared with their cor-
responding healthy twins or siblings (Fig.
3A) (Student’s t-test = 2.589, P = 0.021).
To determine whether this change in
DNA methylation content was associated
with a decrease in the levels of DNA
methyltransferases, we performed quan-
titative RT-PCR of DNMT1 and DNMT3B
and found significant reductions in the
mRNA levels of DNMTs, specifically of
;35% for DNMT1 and 20% for DNMT3B
(Supplemental Fig. 2B).
A global decrease in the 5mC con-
tent cannot exclusively be associated
with changes in the DNA methylation
status of genes, since these constitute
a very small proportion of the total ge-
nomic CpG content. In humans, most of
the methylated cytosines are found in
CpG-rich sequences within tandem and
interspersed repeats that constitute up to
45% of the human genome, and Alu re-
peats are the most common family of
such repeats. We used genome-wide am-
plification of unmethylated DNA Alu re-
peats (AUMA) (Rodriguez et al. 2008) to
Figure 2. A comparison of the DNA methylation levels of eight genes in paired samples discordant for
SLE. Bisulfite pyrosequencing analysis was performed on the genes selected from experiments with
methylation arrays. Methylation levels were normalized by dividing the percentage of methylation for
each particular gene by the average percentage of methylation in the entire population (17 SLE dis-
cordant sibling pairs: six MZ twins, four DZ twins, and seven disease-discordant sibling pairs). Control
samples are ordered right to left by decreasing level of methylation. SLE samples are on the left side of
each graph, and the same order is maintained for their respective healthy twins or siblings. Each bar
graph is accompanied by a scatterplot representing the normalized DNA methylation level of each gene
for the control samples relative to their equivalent SLE sample.
DNA methylome differences in SLE discordant twins
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compare the genomic-scale levels of unmethylated and methyl-
ated Alu elements of a selection of MZ twins discordant for SLE, MZ
twins concordant for SLE, and unrelated healthy MZ twins. No
significant differences were observed (Fig. 3B). The absence of
significant changes was confirmed by performing bisulfite geno-
mic sequencing of a consensus Alu repeat (Fig. 3C), although small
changes in two specific CpGs within the Alu repeat sequence were
observed. Several additional repetitive sequences have been shown
to undergo DNA methylation changes in cancer and to exhibit
a variety of genetic disorders. We decided to analyze the DNA
methylation profile of some of these sequences, including satel-
lite2 repeats, NBL2 and D4Z4 non-satellite subtelomeric repeats,
and LINE-1 repeats. Comparison of the DNA methylation profiles
in the five original MZ twin pairs discordant for SLE that had
previously been shown to have differences in the global content of
5mC showed no significant differences in the DNA methylation
status of any of these repeat sequences (two examples are illus-
trated in Supplemental Fig. 3).
SLE discordant MZ twins are differentially methylated
at ribosomal RNA genes
Ribosomal genes are present in significant copy numbers (150–
300) in mammalian genomes. Interestingly, aberrant changes in
the DNA methylation status of ribosomal
genes, particularly in the transcribed re-
gion containing the 28S, 18S, and 5.8S
that resembles a large CpG island, have
been associated with various disorders.
For instance, in a-thalassemia/mental re-
tardation syndrome X-linked (ATRX),
hypomethylation of the ribosomal genes
at chromosomes 13, 14, 15, 21, and 22 is
known to be associated with mutations
in ATRX, a chromatin remodeling factor
(Gibbons et al. 2000). Also, genetic ma-
nipulation of DNMT levels reduces the
DNA methylation levels of ribosomal
genes (Espada et al. 2007). We therefore
performed bisulfite genomic sequencing
for the five original pairs of MZ twins
discordant for SLE on three regions of the
ribosomal RNA gene cluster: the ribo-
somal gene promoter, 18S, and 28S. Al-
though no significant differences in DNA
methylation were observed in the pro-
moter region, we found a significant de-
crease in the 18S and 28S segments (Fig.
4A) for the SLE sibling of each twin pair.
Healthy siblings of SLE-discordant twin
pairs had similar DNA methylation lev-
els to those of healthy twin pairs and
other unrelated age-, gender-, and race-
matched normal controls (Fig. 4A). In
contrast, individuals from twin pairs
concordant for SLE exhibited low levels
of methylation for the 18S and 28S se-
quences, similar to those of the SLE sib-
ling of discordant twin pairs.
We then performed bisulfite se-
quencing to determine the DNA methyl-
ation status of all 17 pairs of siblings dis-
cordant for SLE and seven pairs of SLE-concordant MZ twins. Our
results confirmed significantly decreased methylation of the 18S
and 28S ribosomal genes in all SLE samples relative to their re-
spective healthy siblings, as revealed by a Student’s t-test (P < 0.05)
(Fig. 4B,C; Supplemental Table 4). Three comparisons were tested:
(1) SLE siblings from discordant twin pairs with their respective
healthy siblings, (2) SLE siblings from discordant twin pairs with
SLE-concordant MZ twins, and (3) healthy siblings from discor-
dant twin pairs with SLE-concordant MZ twins. Unpaired two-
tailed t-tests revealed that 18S and 28S are hypomethylated in SLE
siblings with respect to their corresponding healthy siblings and
that they exhibit similar values to individuals from SLE-concor-
dant MZ twin pairs (Fig. 4B,C).
It is likely that changes in the DNA methylation status of ri-
bosomal genes, even when they occur at regions downstream from
the transcription start site, may affect their transcriptional rate.
Thus, we assessed the effects on rRNA expression at two levels—
first, by looking at the expression levels of the full-length precur-
sor RNA that is transcribed; and, second, by examining the mature
18S RNA. When we compared the expression levels of the pre-
cursor RNA and the 18S RNA by quantitative RT-PCR in the six
pairs of MZ twins discordant for SLE, both transcripts showed
higher levels in all the SLE twins compared with their corre-
sponding healthy twins. This suggests that changes in the DNA
Figure 3. (A) Scatterplot comparing total 5mC content in SLE siblings and their matching healthy
siblings. Data are normalized with respect to the average 5mC methylation content in the entire
population. (B) Band patterning corresponding to the analysis of unmethylated/methylated Alu repeats.
Two SLE discordant MZ twin pairs, two SLE concordant MZ twin pairs, and two concordant pairs of
healthy MZ twins are shown. To show the sensitivity toward DNA methylation changes, a WBC sample is
compared with the same sample following limited treatment with SssI DNA methyltransferase. (C )
Individual bisulfite sequencing of consensus Alu repeat. Fifteen clones are shown. (Black squares)
Methylated CpG sites; (white squares) non-methylated CpG sites. One pair of SLE discordant MZ twins
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methylation profile were directly associated with the increased
transcript levels (Supplemental Fig. 2B). To investigate whether
these changes in the ribosomal RNA genes occurred in conjunction
with changes in the DNA methylation status and/or expression of
ribosomal proteins, for which auto-antibodies have been reported
to be present in SLE patients, we performed bisulfite genomic se-
quencing of the promoter CpG island and quantitative RT-PCR for
RPLP0, RPLP1, and RPLP2 of the six pairs of MZ twins discordant
for SLE. Neither methylation changes nor expression changes were
found when comparing SLE and healthy twins. Further studies will
be necessary to determine the functional relevance of changes at
the DNA methylation and expression levels of ribosomal RNA.
Discussion
Many complementary lines of evidence suggest that epigenetic
factors may play a key role in the pathogenesis of autoimmune
diseases. Interactions between environmental and genetic factors
have been proposed to explain why certain individuals develop
autoimmune disorders while others do not (Gourley and Miller
2007), and provide an explanation for the high discordance rates
for autoimmune diseases in MZ twins. On the other hand, several
SLE susceptibility genes, like STAT4 or MECP2, have mechanistic
connections with DNA methylation. The existence of functionally
relevant polymorphisms in genes that can influence DNA meth-
ylation status also highlights the need to investigate epigenetic
changes involved in this disease.
In this context, our study constitutes an effort to understand
the relevance of DNA methylation alterations in the context of
autoimmune disease. Here we report the first high-throughput
analysis of DNA methylation changes in autoimmune disease. In
addition, we take advantage of the use of MZ twins to screen DNA
methylation changes in the search for evidence that DNA meth-
ylation changes arise from a variety of environmental effects or are
determined by specific genetic features of SLE individuals.
The rationale for the comparison of three autoimmune dis-
eases was based on certain shared clinical signs and symptoms,
immune responses, and common genetic risk factors. Despite
these shared features, however, our data do not suggest the exis-
tence of common targets of epigenetic deregulation in these three
disorders. Nonetheless, the possibility that they share epigenetic
targets cannot be ruled out, and further studies involving the
epigenomic analysis of a wider range of genes and perhaps addi-
tional target tissues are needed.
Figure 4. DNA methylation changes in ribosomal genes in paired samples discordant for SLE. (A) Schematic representation of the rRNA gene depicting
three regions in the gene repeat: the proximal promoter, including the transcription start site, and the initial sections of the 18S and 28S regions, were
subjected to bisulfite genomic sequencing. Fifteen clones are shown. (Black squares) Methylated CpG sites; (white squares) non-methylated CpG sites.
One SLE discordant pair of MZ twins, one SLE concordant pair of MZ twins, and one concordant pair of healthy MZ twins are shown. (B) Heat map
including the normalized methylation data for 17 pairs of SLE-discordant samples and seven pairs of SLE-concordant samples. Data are normalized with
respect to the average value of healthy siblings from discordant twin pairs, and a color scale is established between no-methylation (blue) and methylation
(red) values near the average of normal samples. Three comparisons are made: SLE siblings from discordant pairs versus SLE twins from concordant pairs
(upper P-value); healthy siblings from discordant pairs versus SLE twins from concordant pairs (lower P-value); SLE siblings from discordant pairs versus their
matching healthy twins (P-value at left). (C ) Bar graph showing the average percentage of DNA methylation for the 18S and 28S sequences of SLE siblings
from discordant twin pairs, healthy siblings from discordant twin pairs, and SLE individuals from concordant twin pairs.
DNA methylome differences in SLE discordant twins
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Our results do indicate the existence of a decrease in the DNA
methylation levels of several genes. A few studies have demon-
strated that lymphocyte differentiation and activation are associ-
ated with loss of DNA methylation at key CpGs of promoters
of genes such as interferon gamma and various cytokine genes
(Murayama et al. 2006; Kim et al. 2007). Recent data indicate that
active demethylation in vertebrates takes places through the co-
operation of a deaminase, a mismatch-specific thymine glycosylase,
and the nonenzymatic factor Gadd45 (Rai et al. 2009). Interestingly,
Gadd45a-deficient mice develop a lupus-like syndrome (Salvador
et al. 2002). Given the nature of our biological samples, we cannot
draw any conclusion about the functional meaning of these
methylation changes. However, we cannot discard that differences
in activation of the subpopulations, which have been shown to be
associated with DNA demethylation processes (Murayama et al.
2006; Kim et al. 2007), may participate in those changes. Further
studies using fractionated cell populations will help to associate
specific DNA methylation and gene expression changes with par-
ticular functions. In addition, the use of noninflammatory cell types
such as hepatocytes or myocytes or more accessible cells such as
buccal mucosa or skin will be useful for future studies. At any rate,
WBCs are commonly used in the search for novel SLE targets and
have provided specific signatures associated with SLE pathogenesis
(Bennett et al. 2003; Chaussabel et al. 2008).
The importance of the genes identified in this study in the
context of SLE and other autoimmune diseases becomes more
evident upon performance of Gene Ontology analysis and review
of existing literature. First, Gene Ontology analysis of the set of 49
differentially methylated genes reveals a significant enrichment in
functional processes that are potentially relevant in autoimmune
inflammatory diseases, such as immune response, cell activation,
or response to external stimuli. Second, among the genes that we
have demonstrated to feature lower methylation levels in SLE in-
dividuals than their healthy siblings, we have found several no-
table markers, some of which had been previously referenced
in the context of SLE pathogenesis. For instance, interferon
gamma receptor 2 (IFGNR2) has been shown to be associated with
lymphadenopathy, splenomegaly, and kidney damage in the SLE
mouse model MRL-Faslpr (Schwarting et al. 1998). Recent studies of
interferon activity and lupus have suggested that interferon-stim-
ulated genes, such as AIM2, participate in the development of SLE
(Choubey and Panchanathan 2008). Dysregulation of colony-
stimulating factor 3 receptor (CSF3R) had previously been impli-
cated in the defective expression of CD80 and the subsequent
dysfunction of the antigen-presenting cells in SLE (Funauchi et al.
2002). Matrix metalloproteinases, such as MMP14, contribute to
tissue destruction, regeneration, inflammation, and apoptosis, and
several of them are up-regulated by a range of injuries in the skin
and are thought to be involved in some of the organ manifesta-
tions of SLE. LCN2 is a small protein involved in iron transport and
a common marker for lupus nephritis (Schwartz et al. 2007). LCN2
overexpression has recently been associated with renal dysfunc-
tion and is involved in apoptosis induction (Pitashny et al. 2007).
Finally, CD9 has also been shown to be highly expressed in B-cells
from lupus-prone mice (Duan et al. 2007), although its potential
role in pathogenesis remains to be elucidated.
In parallel, a robust decrease in the global content of DNA
methylation as well as a reduction of DNMT1 and DNMT3B mRNA
levels were observed. Interestingly, mouse knockout models for
Dnmt1 and Dnmt3b have also shown defects in global DNA
methylation (Yung et al. 2001; Dodge et al. 2005). Heterozygous
Dnmt1 null mutation mice developed autoimmunity, although
surprisingly, they displayed increased DNA methylation levels
(Yung et al. 2001). In humans, decreased levels of DNMT1 mRNA
had previously been shown for T-cells isolated from SLE patients
(Deng et al. 2001). Changes in DNMT1 and DNMT3b levels suggest
a potential direct implication in global reduction of 5mC. At any
rate, DNA methylation analysis of a variety of repetitive sequences,
including, Alu, LINE-1, D4Z4, NBL2, and Satellite 2 repeats, did not
show significant differences in methylation between SLE and
healthy individuals. This finding differs from those in cancer and
other diseases, in which a global decrease in the content of 5mC is
accompanied by the loss of methylation in different subsets of
repetitive sequences. For instance, demethylation of Alu elements
occurs in aging and cancer processes and has been associated with
gene reactivation and genomic instability. In immunodeficiency,
centromeric instability and facial anomalies (ICF) syndrome, sat-
ellite repeats, and non-satellite repeats like D4Z4 and NBL2 are
hypomethylated (Kondo et al. 2000). In other cases, such as in
facioscapulohumeral muscular dystrophy (FSHD), DNA methyla-
tion changes are even more localized and exclusively affect D4Z4
repeats (van Overveld et al. 2003). LINE-1 elements are other re-
petitive elements that are sensitive to DNA methylation changes in
cancer or other disorders. We found instead a lower methylation
content in ribosomal sequences. This finding may be of particular
significance, since hypomethylation and overexpression of ribo-
somal RNA genes may be associated with an increased assembly of
ribosomal particles that might stimulate the generation of auto-
antibodies against them. In fact, the presence of auto-antibodies
against ribosomal RNA and proteins in SLE patients has been well
documented over the last three decades. It is unlikely that decrease
in DNA methylation at rRNA genes could solely account for global
changes in the 5mC content, and perhaps other repetitive ele-
ments not assessed may also contribute.
Our investigation demonstrates the utility of twin studies for
identifying epigenetic changes in disease. Given that MZ twins
share their entire genotype (and potentially specific variants in SLE
susceptibility genes), our results reinforce the notion that, for
a particular genetic background, environmental factors can mod-
ulate the onset of SLE. However, at the current stage, we cannot
conclude whether epigenetic changes are cause or consequence; in
other words, whether environmental factors caused the epigenetic
changes in these cell populations, which, in turn, cause the SLE or
whether environmental factors cause the SLE by some unknown
mechanism, which then is accompanied by inflammatory and
immune responses that are secondary to the SLE.
A potential constraint on the use of this approach arises from
the fact that many MZ monochorionic twins exchange blood
through shared vascular communication. Therefore, if any DNA
methylation changes occur in the blood of one of the twins before
birth, it is common for both of them to show it. Only the sibling of
the pair in whom the change has originally occurred might present
the phenotype, because additional cells of the body could be af-
fected. Therefore, MZ twins are a good model system for diseases
that are not congenital, like autoimmune diseases, and that start to
develop after birth, when there is no blood sharing. Our data do
not allow us to conclude the timing of the DNA methylation
changes observed; however, it is likely that they are associated with
the onset of the disease.
Our recent study revealed the existence of epigenetic differ-
ences between MZ twins and demonstrated how these differences
become more pronounced with age, supporting the notion that
‘‘epigenetic drift’’ plays a role in divergence of MZ phenotypes
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further evidence that differences in epigenomes can explain phe-
notypic differences (Kaminsky et al. 2009). Thus, the present re-
port, in which the discordance between twins is used to identify
epigenetic targets, highlights the potential of this strategy for




All subjects, or in the case of children, the parents, gave their in-
formed written consent to be included in the study. Samples were
collected within 4 yr of the affected twins or siblings meeting the
established criteria for disease. Rheumatoid arthritis (RA) and
dermatomyositis (DM) individuals, recruited at the National In-
stitutes of Health (NIH) Clinical Center, respectively, fulfilled the
Bohan and Peter and American College of Rheumatology criteria.
For systemic lupus erythematosus (SLE) individuals, recruited at
NIH Clinical Center and the Oklahoma Medical Research Foun-
dation, the SLE Activity Index (SLEDAI) and Systemic Lupus In-
ternational Collaborative Clinics/American College of Rheuma-
tology (SLICC) Damage Index are shown (see Supplemental Table
4). For array-based DNA methylation profiling, 60 samples corre-
sponding to 15 pairs of MZ twins discordant for disease plus two
additional controls for each twin pair were used; specifically, these
consisted of five pairs for each of the following diseases: SLE, RA,
and DM. For each MZ twin pair, two additional unrelated age-,
gender-, and race-matched healthy controls were used in array-
based DNA methylation profiling. For further DNA methylation
analysis, 17 sibling pairs discordant for SLE were used: the above
five MZ twin pairs plus one additional MZ twin pair, four DZ twin
pairs, and seven non-twin sibling pairs. Also, a set of seven MZ
twins concordant for SLE was included. Homozygosity was de-
termined by using highly polymorphic short tandem-repeat loci.
White blood cells (WBCs) were extracted by standard procedures.
WBC counts performed on an automatic Coulter counter were
available for the majority of the samples. Total DNA was isolated
from WBCs by standard procedures and stored at 80°C.
Quantification of total DNA methylation
5mC content was quantified by high-performance capillary elec-
trophoresis (HPCE), as previously described (Ballestar et al. 2003).
In brief, immunoprecipitated DNA samples were speed-vac pre-
concentrated to 0.1 mg/mL and enzymatically hydrolyzed with
nuclease P1 for 16 h at 37°C, and subsequently treated with alka-
line phosphatase (Sigma-Aldrich) for an additional 2 h at 37°C.
Samples were then directly injected in a Beckman MDQ HPCE
apparatus. 5mC content was determined as the percentage of 5mC
of total cytosines: 5mC peak area 3 100/(C peak area + 5mC peak
area).
DNA methylation profiling using universal bead arrays
A GoldenGate Methylation Cancer Panel I (Illumina) was used to
quantify DNA methylation. The panel was developed to assay
1505 CpG sites selected from 807 genes, including oncogenes and
tumor-suppressor genes, genes previously reported to be differen-
tially methylated or differentially expressed, imprinted genes,
genes involved in various signaling pathways, and genes re-
sponsible for DNA repair, cell cycle control, metastasis, differenti-
ation, and apoptosis. For each CpG site, four probes were designed:
two allele-specific oligos (ASOs) and two locus-specific oligos
(LSOs). Each ASO-LSO oligo pair corresponded to either the
methylated or unmethylated state of the CpG site. The re-
producibility and validity of this array has been extensively vali-
dated (Bibikova et al. 2006). Bisulfite conversion of DNA samples
was done using the EZ DNA methylation kit (Zymo Research). After
this, the remaining steps were identical to those of the GoldenGate
genotyping assay, using reagents and conditions supplied and
recommended by Illumina. Two technical replicates of each bi-
sulfite-converted sample were run. The results were all in close
agreement and were averaged for subsequent analysis. The array
was hybridized under a temperature gradient program, and arrays
were imaged using a BeadArray Reader (Illumina). Image process-
ing and intensity data extraction software and procedures were
those described in Bibikova et al. (2006). Each methylation data
point was represented as a combination of the Cy3 and Cy5 fluo-
rescent intensities (Supplemental Data 1) from the M (methylated)
and U (unmethylated) alleles (Supplemental Data 2). Background
intensity computed from a set of negative controls was subtracted
from each data point.
Detection of differentially methylated genes
from the methylation array and functional analysis
A t-test was carried out as implemented in the GEPAS package
(Montaner et al. 2006) to identify probes differentially methylated
between SLE versus their respective healthy twins. P-values were
corrected for multiple testing using the method proposed by
Benjamini and Hochberg (1995) to control for the false discovery
rate (FDR). Genes showing a P-value < 0.05 (or FDR < 0.25) and
a minimum mean methylation change of 10% were considered
differentially methylated. Gene Ontology analysis was done with
the FatiGO tool (Al-Shahrour et al. 2004), which uses a statistical
test (Fisher’s exact test) to detect significant over-representation of
GO terms in one of the sets (list of selected genes) with respect to
the other one (the rest of the genome). Multiple test correction to
account for the multiple hypothesis tested (one for each GO term) is
applied to reduce false positives. GO terms with adjusted P-value #
0.05 are considered significant. The relationship between the DNA
methylation data (from standard bisulfite sequencing and/or
quantitative bisulfite pyrosequencing) and the clinical data from
the SLE individuals (activity and damage indexes), age and race were
evaluated by the Pearson x2-test. Multiple testing was performed for
the SLE/Healthy MZ twin pair DNA methylation of resulting genes
from the methylation array analysis and WBC counts.
Amplification of unmethylated Alus (AUMA)
DNA digestion with SmaI enzyme and ligation to the linker was
performed as described (Rodriguez et al. 2008). The product was
purified using the GFX Kit (Amersham Biosciences) and eluted in
250 mL of sterile water. A chimeric primer comprised of the com-
plementary linker sequence (ATTCGCAAAGCTCTGA), the cut
SmaI site (GGG), and three additional nucleotides homologous to
the Alu consensus sequence were used to enrich for Alu sequences:
AUMA-TTC (ATTCGCAAAGCTCTGAGGGTTC). In each PCR re-
action only one primer was used at a time. Products were resolved
on denaturing sequencing gels. Bands were visualized by silver-
staining the gels. Faint bands with inconsistent display due to
small variations in gel electrophoresis resolution were not con-
sidered. Band reproducibility was assessed with the analysis of PCR
duplicates. AUMA fingerprints were visually checked for methyl-
ation differences between bands in different samples. Under these
premises, a given band was scored according to three possible
behaviors: hypomethylation (increased intensity), hypermeth-
ylation (decreased intensity), and no change (no substantial
difference between samples). Only those bands showing clear
DNA methylome differences in SLE discordant twins
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changes in their intensities in the fingerprint were considered to
represent methylation changes.
Analysis of gene promoter methylation: Bisulfite sequencing
and pyrosequencing
The CpG island DNA methylation status was determined by se-
quencing bisulfite-modified genomic DNA. Bisulfite modification
of genomic DNA was carried out as described by Herman et al.
(1996). For each gene, primers were designed using the Methyl
Primer Express v1.0 program (Applied Biosystems) corresponding
to the region containing the oligonucleotide probe represented in
the DNA methylation bead array. To validate the DNA methylation
data obtained by conventional bisulfite genomic sequencing on
a larger scale, bisulfite pyrosequencing (BPS) was performed ac-
cording to standard protocols and evaluated with the Pyro Q-CpG
1.0.9 program (Biotage). Primer sequences, product lengths, and
annealing temperatures used in the bisulfite sequencing and BPS
PCR reactions are shown in Supplemental Table 5.
Quantitative RT-PCR expression analyses
We reverse-transcribed total RNA (2 mg), treated with DNase
(Ambion) using SuperScript II Reverse Transcriptase from Invi-
trogen. Quantitative real-time PCR (Q-RT-PCR) analysis was per-
formed on an ABI 7900HT with Sybr green. Primer sequences are
shown in Supplemental Table 5.
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Montaner D, Tárraga J, Huerta-Cepas J, Burguet J, Vaquerizas JM, Conde L,
Minguez P, Vera J, Mukherjee S, Valls J. 2006. Next station in microarray
data analysis: GEPAS. Nucleic Acids Res 34: W486–W491.
Moser KL, Kelly JA, Lessard CJ, Harley JB. 2009. Recent insights into the




 Cold Spring Harbor Laboratory Press on May 28, 2020 - Published by genome.cshlp.orgDownloaded from 
Murayama A, Sakura K, Nakama M, Yasuzawa-Tanaka K, Fujita E, Tateishi Y,
Wang Y, Ushijima T, Baba T, Shibuya K. 2006. A specific CpG site
demethylation in the human interleukin 2 gene promoter is an
epigenetic memory. EMBO J 25: 1081–1092.
Nance WE, ed. 1978. Twin research, Part C: Clinical studies. Alan R Liss, New
York.
Pitashny M, Schwartz N, Qing X, Hojaili B, Aranow C, Mackay M, Putterman
C. 2007. Urinary lipocalin-2 is associated with renal disease activity
in human lupus nephritis. Arthritis Rheum 56: 1894–1903.
Rai K, Huggins IJ, James SR, Karpf AR, Jones DA, Cairns BR. 2009. DNA
demethylation in zebrafish involves the coupling of a deaminase,
a glycosylase, and gadd45. Cell 135: 1201–1212.
Richardson B. 1986. Effect of an inhibitor of DNA methylation on T cells. II.
5-Azacytidine induces self-reactivity in antigen-specific T4+ cells. Hum
Immunol 17: 456–470.
Richardson B, Scheinbart L, Strahler J, Gross L, Hanash S, Johnson M. 1990.
Evidence for impaired T cell DNA methylation in systemic lupus
erythematosus and rheumatoid arthritis. Arthritis Rheum 33: 1665–
1673.
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